Acetylcholine

Chemistry

Acetylcholine is a choline molecule that has been acetylated at the oxygen atom. Because of the charged ammonium group, acetylcholine does not penetrate lipid membranes. Because of this, when the molecule is introduced externally, it remains in the extracellular space and at present it is considered that the molecule does not pass through the blood–brain barrier.

Biochemistry

Acetylcholine is synthesized in certain neurons by the enzyme choline acetyltransferase from the compounds choline and acetyl-CoA. Cholinergic neurons are capable of producing ACh. An example of a central cholinergic area is the nucleus basalis of Meynert in the basal forebrain. The enzyme acetylcholinesterase converts acetylcholine into the inactive metabolites choline and acetate. This enzyme is abundant in the synaptic cleft, and its role in rapidly clearing free acetylcholine from the synapse is essential for proper muscle function. Certain neurotoxins work by inhibiting acetylcholinesterase, thus leading to excess acetylcholine at the neuromuscular junction, causing paralysis of the muscles needed for breathing and stopping the beating of the heart.

Functions

Acetylcholine functions in both the central nervous system (CNS) and the peripheral nervous system (PNS). In the CNS, cholinergic projections from the basal forebrain to the cerebral cortex and hippocampus support the cognitive functions of those target areas. In the PNS, acetylcholine activates muscles and is a major neurotransmitter in the autonomic nervous system.

Cellular effects

Main article: Acetylcholine receptor

Like many other biologically active substances, acetylcholine exerts its effects by binding to and activating receptors located on the surface of cells. There are two main classes of acetylcholine receptor, nicotinic and muscarinic. They are named for chemicals that can selectively activate each type of receptor without activating the other: muscarine is a compound found in the mushroom Amanita muscaria; nicotine is found in tobacco.

Nicotinic acetylcholine receptors are ligand-gated ion channels permeable to sodium, potassium, and calcium ions. In other words, they are ion channels embedded in cell membranes, capable of switching from a closed to an open state when acetylcholine binds to them; in the open state they allow ions to pass through. Nicotinic receptors come in two main types, known as muscle-type and neuronal-type. The muscle-type can be selectively blocked by curare, the neuronal-type by hexamethonium. The main location of muscle-type receptors is on muscle cells, as described in more detail below. Neuronal-type receptors are located in autonomic ganglia (both sympathetic and parasympathetic), and in the central nervous system.

Muscarinic acetylcholine receptors have a more complex mechanism, and affect target cells over a longer time frame. In mammals, five subtypes of muscarinic receptors have been identified, labeled M1 through M5. All of them function as G protein-coupled receptors, meaning that they exert their effects via a second messenger system. The M1, M3, and M5 subtypes are Gq-coupled; they increase intracellular levels of IP3 and calcium by activating phospholipase C. Their effect on target cells is usually excitatory. The M2 and M4 subtypes are Gi/Go-coupled; they decrease intracellular levels of cAMP by inhibiting adenylate cyclase. Their effect on target cells is usually inhibitory. Muscarinic acetylcholine receptors are found in both the central nervous system and the peripheral nervous system of the heart, lungs, upper gastrointestinal tract, and sweat glands.

Neuromuscular junction

Main article: Neuromuscular junction

Acetylcholine is the substance the nervous system uses to activate skeletal muscles, a kind of striated muscle. These are the muscles used for all types of voluntary movement, in contrast to smooth muscle tissue, which is involved in a range of involuntary activities such as movement of food through the gastrointestinal tract and constriction of blood vessels. Skeletal muscles are directly controlled by motor neurons located in the spinal cord or, in a few cases, the brainstem. These motor neurons send their axons through motor nerves, from which they emerge to connect to muscle fibers at a special type of synapse called the neuromuscular junction.

When a motor neuron generates an action potential, it travels rapidly along the nerve until it reaches the neuromuscular junction, where it initiates an electrochemical process that causes acetylcholine to be released into the space between the presynaptic terminal and the muscle fiber. The acetylcholine molecules then bind to nicotinic ion-channel receptors on the muscle cell membrane, causing the ion channels to open. Sodium ions then flow into the muscle cell, initiating a sequence of steps that finally produce muscle contraction.

Factors that decrease release of acetylcholine (and thereby affecting P-type calcium channels):

1. Antibiotics (clindamycin, polymyxin)
2. Magnesium: antagonizes P-type calcium channels
3. Hypocalcemia
4. Anticonvulsants
5. Diuretics (furosemide)
6. Eaton-Lambert syndrome: inhibits P-type calcium channels
7. Myasthenia gravis
8. Botulinum toxin: inhibits SNARE proteins

Calcium channel blockers (nifedipine, diltiazem) do not affect P-channels. These drugs affect L-type calcium channels.

Autonomic nervous system

The autonomic nervous system controls a wide range of involuntary and unconscious body functions. Its main branches are the sympathetic nervous system and parasympathetic nervous system. Broadly speaking, the function of the sympathetic nervous system is to mobilize the body for action; the phrase often invoked to describe it is fight-or-flight. The function of the parasympathetic nervous system is to put the body in a state conducive to rest, regeneration, digestion, and reproduction; the phrase often invoked to describe it is "rest and digest" or "feed and breed". Both of these aforementioned systems use acetylcholine, but in different ways.

At a schematic level, the sympathetic and parasympathetic nervous systems are both organized in essentially the same way: preganglionic neurons in the central nervous system send projections to neurons located in autonomic ganglia, which send output projections to virtually every tissue of the body. In both branches the internal connections, the projections from the central nervous system to the autonomic ganglia, use acetylcholine as a neurotransmitter to innervate (or excite) ganglia neurons. In the parasympathetic nervous system the output connections, the projections from ganglion neurons to tissues that do not belong to the nervous system, also release acetylcholine but act on muscarinic receptors. In the sympathetic nervous system the output connections mainly release noradrenaline, although acetylcholine is released at a few points, such as the sudomotor innervation of the sweat glands.

Direct vascular effects

Acetylcholine in the serum exerts a direct effect on vascular tone by binding to muscarinic receptors present on vascular endothelium. These cells respond by increasing production of nitric oxide, which signals the surrounding smooth muscle to relax, leading to vasodilation.

Central nervous system

In the central nervous system, ACh has a variety of effects on plasticity, arousal and reward. ACh has an important role in the enhancement of alertness when we wake up, in sustaining attention and in learning and memory.

Damage to the cholinergic (acetylcholine-producing) system in the brain has been shown to be associated with the memory deficits associated with Alzheimer's disease. ACh has also been shown to promote REM sleep.

In the brainstem acetylcholine originates from the Pedunculopontine nucleus and laterodorsal tegmental nucleus collectively known as the mesopontine tegmentum area or pontomesencephalotegmental complex. In the basal forebrain, it originates from the basal nucleus of Meynert and medial septal nucleus:

• The pontomesencephalotegmental complex acts mainly on M1 receptors in the brainstem, deep cerebellar nuclei, pontine nuclei, locus coeruleus, raphe nucleus, lateral reticular nucleus and inferior olive. It also projects to the thalamus, tectum, basal ganglia and basal forebrain.
• Basal nucleus of Meynert acts mainly on M1 receptors in the neocortex.
• Medial septal nucleus acts mainly on M1 receptors in the hippocampus and parts of the cerebral cortex.

In addition, ACh acts as an important internal transmitter in the striatum, which is part of the basal ganglia. It is released by cholinergic interneurons. In humans, non-human primates and rodents, these interneurons respond to salient environmental stimuli with responses that are temporally aligned with the responses of dopaminergic neurons of the substantia nigra.

Memory

Acetylcholine has been implicated in learning and memory in several ways. The anticholinergic drug scopolamine impairs acquisition of new information in humans and animals. In animals, disruption of the supply of acetylcholine to the neocortex impairs the learning of simple discrimination tasks, comparable to the acquisition of factual information and disruption of the supply of acetylcholine to the hippocampus and adjacent cortical areas produces forgetfulness, comparable to anterograde amnesia in humans.

Acetylcholine (ACh) has traditionally been seen as vital for learning and memory, but recent studies question its purely positive role. Too much ACh can interfere with memory consolidation, particularly during sleep, and may worsen verbal memory in early Alzheimer’s disease (AD) and mild cognitive impairment (MCI). Excessive activation of ACh pathways can also overstimulate glutamate activity, contributing to AD progression. Researchers propose that ACh levels first increase and later decrease throughout AD and Parkinson’s disease dementia (PDD), due to initial overstimulation followed by neuron loss. They emphasize that cholinesterase inhibitors may not help all cognitive symptoms and could disrupt natural ACh balance, showing that ACh’s effects on memory are complex and require further investigation.

Diseases and disorders

Myasthenia gravis

The disease myasthenia gravis, characterized by muscle weakness and fatigue, occurs when the body inappropriately produces antibodies against acetylcholine nicotinic receptors, and thus inhibits proper acetylcholine signal transmission. Over time, the motor end plate is destroyed. Drugs that competitively inhibit acetylcholinesterase (e.g., neostigmine, physostigmine, or primarily pyridostigmine) are effective in treating the symptoms of this disorder. They allow endogenously released acetylcholine more time to interact with its respective receptor before being inactivated by acetylcholinesterase in the synaptic cleft (the space between nerve and muscle).

Nerves release ACh at the neuromuscular junction. ACh binds to ACh receptors on the muscle surface and causes muscle contraction. Then the immune system produces autoantibodies that attack or black the ACh receptors on the muscle. Therefore, the signal from the nerve to the muscle is weakened or lost. Juvenile MG is more frequently seen in people of Asian and African descent.

Pharmacology

Blocking, hindering or mimicking the action of acetylcholine has many uses in medicine. Drugs acting on the acetylcholine system are either agonists to the receptors, stimulating the system, or antagonists, inhibiting it. Acetylcholine receptor agonists and antagonists can either have an effect directly on the receptors or exert their effects indirectly, e.g., by affecting the enzyme acetylcholinesterase, which degrades the receptor ligand. Agonists increase the level of receptor activation; antagonists reduce it.

Acetylcholine itself does not have therapeutic value as a drug for intravenous administration because of its multi-faceted action (non-selective) and rapid inactivation by cholinesterase. However, it is used in the form of eye drops to cause constriction of the pupil during cataract surgery, which facilitates quick post-operational recovery.

Nicotinic receptors

Main article: Nicotinic receptor

Nicotine binds to and activates nicotinic acetylcholine receptors, mimicking the effect of acetylcholine at these receptors. ACh opens a Na+ channel upon binding so that Na+ flows into the cell. This causes a depolarization, and results in an excitatory post-synaptic potential. Thus, ACh is excitatory on skeletal muscle; the electrical response is fast and short-lived. Curares are arrow poisons, which act at nicotinic receptors and have been used to develop clinically useful therapies.

Muscarinic receptors

Main article: Muscarinic receptor

Muscarinic receptors form G protein-coupled receptor complexes in the cell membranes of neurons and other cells. Atropine is a non-selective competitive antagonist with Acetylcholine at muscarinic receptors.

Cholinesterase inhibitors

Main article: Cholinesterase inhibitors

Many ACh receptor agonists work indirectly by inhibiting the enzyme acetylcholinesterase. The resulting accumulation of acetylcholine causes continuous stimulation of the muscles, glands, and central nervous system, which can result in fatal convulsions if the dose is high.

They are examples of enzyme inhibitors, and increase the action of acetylcholine by delaying its degradation; some have been used as nerve agents (Sarin and VX nerve gas) or pesticides (organophosphates and the carbamates). Many toxins and venoms produced by plants and animals also contain cholinesterase inhibitors. In clinical use, they are administered in low doses to reverse the action of muscle relaxants, to treat myasthenia gravis, and to treat symptoms of Alzheimer's disease (rivastigmine, which increases cholinergic activity in the brain).

Synthesis inhibitors

Organic mercurial compounds, such as methylmercury, have a high affinity for sulfhydryl groups, which causes dysfunction of the enzyme choline acetyltransferase. This inhibition may lead to acetylcholine deficiency, and can have consequences on motor function.

Release inhibitors

Botulinum toxin (Botox) acts by suppressing the release of acetylcholine, whereas the venom from a black widow spider (alpha-latrotoxin) has the reverse effect. ACh inhibition causes paralysis. When bitten by a black widow spider, one experiences the wastage of ACh supplies and the muscles begin to contract. If and when the supply is depleted, paralysis occurs.

Photopharmacological agents

Photopharmacology is an emerging field that uses light to control the activity of biologically active compounds with high spatial and temporal precision. Recent advances have applied this approach to the cholinergic system, including photoactivatable agonists and antagonists of muscarinic and nicotinic acetylcholine receptors, as well as light-sensitive acetylcholinesterase inhibitors, that enable reversible and targeted modulation of cholinergic signaling upon irradiation. These light-regulated compounds, based on either photolabile protecting groups ("caged" ligands) or photoisomerizable scaffolds, offer unprecedented control over acetylcholine-mediated processes and represent promising tools for both basic research and potential therapeutic applications.

Comparative biology and evolution

Acetylcholine is used by organisms in all domains of life for a variety of purposes. It is believed that choline, a precursor to acetylcholine, was used by single celled organisms billions of years ago for synthesizing cell membrane phospholipids. Following the evolution of choline transporters, the abundance of intracellular choline paved the way for choline to become incorporated into other synthetic pathways, including acetylcholine production. Acetylcholine is used by bacteria, fungi, and a variety of other animals. Many of the uses of acetylcholine rely on its action on ion channels via GPCRs like membrane proteins.

The two major types of acetylcholine receptors, muscarinic and nicotinic receptors, have convergently evolved to be responsive to acetylcholine. This means that rather than having evolved from a common homolog, these receptors evolved from separate receptor families. It is estimated that the nicotinic receptor family dates back longer than 2.5 billion years. Likewise, muscarinic receptors are thought to have diverged from other GPCRs at least 0.5 billion years ago. Both of these receptor groups have evolved numerous subtypes with unique ligand affinities and signaling mechanisms. The diversity of the receptor types enables acetylcholine to create varying responses depending on which receptor types are activated, and allow for acetylcholine to dynamically regulate physiological processes. ACh receptors are related to 5-HT3 (serotonin), GABA, and Glycine receptors, both in sequence and structure, strongly suggesting that they have a common evolutionary origin.

History

In 1867, Adolf von Baeyer resolved the structures of choline and acetylcholine and synthesized them both, referring to the latter as acetylneurin in the study. Choline is a precursor for acetylcholine. Acetylcholine was first noted to be biologically active in 1906, when Reid Hunt (1870–1948) and René de M. Taveau found that it decreased blood pressure in exceptionally tiny doses. This was after Frederick Walker Mott and William Dobinson Halliburton noted in 1899 that choline injections decreased the blood pressure of animals.

In 1914, Arthur J. Ewins was the first to extract acetylcholine from nature. He identified it as the blood pressure-decreasing contaminant from some Claviceps purpurea ergot extracts, by the request of Henry Hallett Dale.

The concept of neurotransmitters was unknown until 1921, when Otto Loewi noted that the vagus nerve secreted a substance that inhibited the heart muscle whilst working as a professor in the University of Graz. He named it vagusstoff ("vagus substance"), noted it to be a structural analog of choline and suspected it to be acetylcholine. In 1926, Loewi and E. Navratil deduced that the compound is probably acetylcholine, as vagusstoff and synthetic acetylcholine lost their activity in a similar manner when in contact with tissue lysates that contained acetylcholine-degrading enzymes (now known to be cholinesterases). This conclusion was accepted widely. Later studies confirmed the function of acetylcholine as a neurotransmitter.

In 1936, H. H. Dale and O. Loewi shared the Nobel Prize in Physiology or Medicine for their studies of acetylcholine and nerve impulses.

References

References

1. Lawrence, Eleanor. (1989). "ACh".
2. (October 2012). "Basic and modern concepts on cholinergic receptor: A review.". Asian Pacific Journal of Tropical Disease.
3. (2023). "StatPearls". StatPearls Publishing.
4. (June 2019). "StatPearls". StatPearls Publishing.
5. (2010). "Nutritional and Herbal Therapies for Children and Adolescents". Elsevier.
6. (March 2018). "Traced on the Timeline: Discovery of Acetylcholine and the Components of the Human Cholinergic System in a Primitive Unicellular Eukaryote ''Acanthamoeba'' spp.". ACS Chem Neurosci.
7. (June 2017). "Evidence of a M1-muscarinic GPCR homolog in unicellular eukaryotes: featuring ''Acanthamoeba'' spp bioinformatics 3D-modelling and experimentations". J. Recept. Signal Transduct. Res..
8. (2018). "Применение атропина для контроля прогрессирования миопии". Vestnik Oftalmologii.
9. (November 2018). "The Beat Goes On: The Story of Five Ageless Cardiac Drugs". The American Journal of the Medical Sciences.
10. (March 2016). "Pharmacological management of anticholinergic delirium - theory, evidence and practice". British Journal of Clinical Pharmacology.
11. (2009). "Philosophy, perception, and neuroscience". Perception.
12. (2016). "The Nature and Function of Digital Information Compression Mechanisms in the Brain and in Digital Television Technology". Front Syst Neurosci.
13. (2023). "StatPearls". StatPearls Publishing.
14. (1 January 2009). "Miller's Anesthesia". Elsevier Health Sciences.
15. (February 2005). "Acetylcholine-induced vasodilation is mediated by nitric oxide and prostaglandins in human skin". J. Appl. Physiol..
16. (November 2005). "From waking to sleeping: neuronal and chemical substrates". Trends Pharmacol. Sci..
17. (June 2000). "Increases in cortical acetylcholine release during sustained attention performance in rats". Brain Res Cogn Brain Res.
18. (1984). "An involvement of acetylcholine in object discrimination learning and memory in the marmoset". Neuropsychologia.
19. (February 1999). "The cholinergic hypothesis of Alzheimer's disease: a review of progress". J. Neurol. Neurosurg. Psychiatry.
20. (August 2011). "The cholinergic system, EEG and sleep". Behav. Brain Res..
21. (May 1986). "Cholinergic systems in the rat brain: III. Projections from the pontomesencephalic tegmentum to the thalamus, tectum, basal ganglia, and basal forebrain". Brain Res. Bull..
22. (December 1989). "Cholinergic systems in the rat brain: IV. Descending projections of the pontomesencephalic tegmentum". Brain Res. Bull..
23. (December 2011). "Spontaneous firing and evoked pauses in the tonically active cholinergic interneurons of the striatum". Neuroscience.
24. (July 2004). "Coincident but distinct messages of midbrain dopamine and striatal tonically active neurons". Neuron.
25. (October 1973). "An analysis of the learning deficit following hyoscine administration to man". Br. J. Pharmacol..
26. (June 1986). "Learning impairment following lesion of the basal nucleus of Meynert in the marmoset: modification by cholinergic drugs". Brain Res..
27. (July 2002). "Unilateral lesions of the cholinergic basal forebrain and fornix in one hemisphere and inferior temporal cortex in the opposite hemisphere produce severe learning impairments in rhesus monkeys". Cereb. Cortex.
28. Huang, Q., Liao, C., Ge, F., Ao, J., Liu, T. (2022). Acetylcholine bidirectionally regulates learning and memory,Journal of Neurorestoratology, 10(2), 100002, ISSN 2324-2426,https://doi.org/10.1016/j.jnrt.2022.100002.
29. (2024). "Neurologic Channelopathies".
30. (January 2024). "Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future". CNS Drugs.
31. Dresser, L., Wlodarski, R., Rezania, K., & Soliven, B. (2021). Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. Journal of Clinical Medicine, 10(11), 2235. https://doi.org/10.3390/jcm10112235
32. (July 2025). "Light-Activated Pharmacological Tools for Exploring the Cholinergic System". Medicinal Research Reviews.
33. (November 2009). "Evolution of the human CNS cholineric system: has this resulted in the emergence of psychiatric disease?". Aust N Z J Psychiatry.
34. (March 1995). "Evolutionary history of the ligand-gated ion-channel superfamily of receptors". Trends in Neurosciences.
35. (1867). "I. Üeber das neurin". Justus Liebigs Ann Chem.
36. (2015). "Non-neuronal cholinergic system in regulation of immune function with a focus on α7 nAChRs". International Immunopharmacology.
37. (1906). "On the physiological action of certain choline derivatives and new methods for detecting choline". BMJ.
38. (April 1982). "Suxamethonium-the development of a modern drug from 1906 to the present day". Medical History.
39. (1899). "VII. The physiological action of choline and neurine". Philosophical Transactions of the Royal Society of London. Series B, Containing Papers of a Biological Character.
40. (1922). "Über humorale übertragbarkeit der herznervenwirkung". Pflug Arch Ges Phys.
41. (1926). "Über humorale übertragbarkeit der herznervenwirkung". Pflug Arch Ges Phys.
42. (March 2006). "Otto Loewi and the chemical transmission of vagus stimulation in the heart". Clinical Cardiology.
43. (2012). "A brief history of choline". Annals of Nutrition & Metabolism.